He claimed that Gavi had “ignored the science” about vaccine safety. He had already dismissed all seventeen members of the C.D.C.’s Advisory Committee on Immunization Practices, before saying that his ...

Also, allergy symptoms tend to be more persistent than cold symptoms, and will only subside when treated with medication ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

A CDC advisory panel on Thursday voted 5-2 to recommend the use of a new preventative RSV therapy in babies, Merck’s ...

The vote offers a sigh of relief to doctors and public health experts worried about vaccine skepticism creeping into policymaking.

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

CDC advisers recommend Merck's Enflonsia to protect babies from RSV, addressing the leading cause of infant hospitalization ...

Moderna receives US FDA approval for RSV vaccine, mResvia, in adults aged 18-59 at increased risk for RSV disease. News release. Moderna. June 12, 2025.

Abrysvo also is approved for prevention of LRTD caused by RSV in adults ages 18 to 59 years who are at increased risk, and for immunization in pregnancy at 32 to 36 weeks' gestational age for the ...

Merck & Co. won US approval for a shot that protects against RSV, the most common cause of hospitalization among infants.